Journal
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
Volume 44, Issue 7, Pages 548-550Publisher
INFORMA HEALTHCARE
DOI: 10.3109/00365548.2012.663931
Keywords
Bone infection; linezolid; rifampicin; methicillin-resistant staphylococci; orthopaedic implant infections
Categories
Ask authors/readers for more resources
Methicillin-resistant Staphylococcus is a common cause of orthopaedic implant infections. In such cases, rifampicin is the antibiotic of choice, but it should not be administered alone to avoid the selection of resistant mutants. Linezolid has activity against resistant staphylococci and a high oral bioavailability; therefore, it could be a good option for combining with rifampicin. We describe 2 patients admitted to our hospital due to orthopaedic implant infections, who received combination therapy with linezolid and rifampicin. In both cases, the trough serum concentration of linezolid during rifampicin treatment was below the minimum inhibitory concentration required to inhibit the growth of 90% of organisms (MIC 90) for staphylococci, but increased after rifampicin withdrawal. This finding suggests an interaction between rifampicin and linezolid, and a possible explanation is discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available